Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication

American Journal of Gastroenterology

Volumn 101, Issue 9, 2006, Pages 1985-1990

  Nista, Enrico C ^a   Candelli, Marcello ^a   Zocco, Maria A ^a   Cremonini, Filippo ^a   Ojetti, Veronica ^a   Finizio, Rosalba ^a   Spada, Cristiano ^a   Cammarota, Giovanni ^a   Gasbarrini, Giovanni ^a   Gasbarrini, Antonio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; UREA;

ABDOMINAL PAIN; ANOREXIA; ARTICLE; BLOATING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; ERADICATION THERAPY; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; NAUSEA; PATIENT COMPLIANCE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TASTE DISORDER; TREATMENT WITHDRAWAL; VOMITING;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BIOPSY; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; ENDOSCOPY, GASTROINTESTINAL; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; OFLOXACIN; OMEPRAZOLE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33748341700     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00716.x     Document Type: Article

References (39)

1. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 1992;116:705-8.
2. Sung JJ, Chung SC, Ling TK, et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 1995;332:139-42.
3. Wotherspoon AC, Doglioni C, de Boni M, et al. Antibiotic treatment for low-grade gastric MALT lymphoma. Lancet 1994;343:1503.
4. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998;93:2330-8.
5. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
6. Houben MH, Van Der Beek D, Hensen EF, et al. A systematic review of Helicobacter pylori eradication therapy. The impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999;13:1047-55.
7. Bock H, Koop H, Lehn N, et al. Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: Preliminary experience. J Clin Gastroenterol 2000;31:222-5.
8. Perri F, Festa V, Clemente R, et al. Rifabutin-based rescue therapy for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000;14:311-6.
9. Canducci F, Ojetti V, Pola P, et al. Letter to editors: Rifabutin-based Helicobacter pylori eradication rescue therapy. Aliment Pharmacol Ther 2001;15:143.
10. Schito AM, Schito GC. Levofloxacin, a broad spectrum anti-infective: From Streptococcus pneumoniae to Pseudomonas aeruginosa. J Chemother 2004;16(suppl 2):3-7.
11. Candelli M, Nista EC, Carloni E, et al. Treatment of H. pylori infection: A review. Curr Med Chem 2005;12:375-84.
12. Blondeau JM, Laskowiski R, Bjarnason J, et al. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int J Antimicrob Agents 2000;14:45-50.
13. Just PM. Overview of the fluoroquinolone antibiotics. Pharmacotherapy 1993;13:4S-17S.
14. Sprandel KA, Rodvold KA. Safety and tolerability of fluoroquinolones. Clin Cornerstone 2003;(suppl 3):S29-S36.
15. Edlund C, Nord CE. Effect of quinolones on intestinal ecology. Drugs 1999;58(suppl 2):65-70.
16. Nightingale Ch. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: A review of microbiologic and pharmacokinetic-pharmaco dynamic characteristics. Pharmacotherapy 2000;20:245-56.
17. Balfour JA, Lamb HM. Moxifloxacin: A review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 2000;59:115-39.
18. Cammarota G, Cianci R, Cannizzaro O, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:1339-43.
19. Di Caro S, Assunta ZM, Cremonini F, et al. Levofloxacin based regimens for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 2002;14:1309-12.
20. Cammarota G, Cianci R, Cannizzaro O, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:1339-43.
21. Wong WM, Gu Q, Lam SK, et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17:553-60.
22. Nista EC, Candelli M, Cremonini F, et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: A randomized trial. Aliment Pharmacol Ther 2003;18:627-33.
23. Bilardi C, Dulbecco P, Zentilin P, et al. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: A controlled trial. Clin Gastroenterol Hepatol 2004;2:997-1002.
24. Moher D, Schulz KF, Altman DG. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001;357:1191-4.
25. Talley N, Colin-Jones D, Koch KL, et al. Functional dyspepsia: A classification with guidelines for diagnosis and management. Gastroenterol Int 1991;4:145-60.
26. de Boer WA, Thys JC, Borody TJ, et al. Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens. Eur J Gastroenterol Hepatol 1996;8:641-3.
27. Huang J, Hunt RH. The importance of clarithromycin dose in the management of Helicobacter pylori infection: A meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Aliment Pharmacol Ther 1999;13:719-29.
28. Hoshiya S, Watanabe K, Tokunaga K, et al. Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan. J Gastroenterol 2000;35:10-4.
29. Kato M, Yamaoka Y, Kim JJ, et al. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother 2000;44:2214-6.
30. Wang WH, Wong BC, Mukhopadhyay AK, et al. High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. Aliment Pharmacol Ther 2000;14:901-10.
31. Pilotto A, Rassu M, Leandro G, et al. Prevalence of Helicobacter pylori resistance to antibiotics in northeast Italy: A multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer. Dig Liver Dis 2000;32:763-8.
32. Tucci A, Varoli O, Corinaldesi R, et al. Evaluation of Helicobacter pylori sensitivity to amoxycillin and metronidazole in dyspeptic patients. Ital J Gastroenterol 1993;25:65-7.
33. Gupta VK, Dhar A, Srinivasan S, et al. Eradication of H. pylori in a developing country: Comparison of lansoprazole versus omeprazole with norfloxacin, in a dual-therapy study. Am J Gastroenterol 1997;92:1140-2.
34. Ahuja V, Dhar A, Bal C, et al. Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country. Aliment Pharmacol Ther 1998;12:551-5.
35. Sharara AI, Chaar HF, Racoubian E, et al. Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection. Helicobacter 2004;9:255-61.
36. Cammarota G, Cianci R, Cannizzaro O, et al. High-dose versus low-dose clarithromycin in 1-week triple therapy, including rabeprazole and levofloxacin, for Helicobacter pylori eradication. J Clin Gastroenterol 2004;38:110-4.
37. Pestova E, Millichap JJ, Noskin GA, et al. Intracellular targets of moxifloxacin: A comparison with other fluoroquinolones. J Antimicrob Chemother 2000;19:228-32.
38. Maggiolo F, Capra R, Bartoli A, et al. Effects of subinhibitory concentrations of moxifloxacin in an in-vitro dynamic model. J Chemother 2000;12:129-33.
39. Boswell FJ, Andrews JM, Wise R, et al. Bactericidal properties of moxifloxacin and post-antibiotic effect. J Antimicrob Chemother 1999;43(suppl B):43-9.